NASDAQ:LIMN

Liminatus Pharma Q3 2025 Earnings Results & Report

Liminatus Pharma logo
$2.51 -0.30 (-10.68%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.68 +0.17 (+6.77%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liminatus Pharma reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$3.50.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Liminatus Pharma EPS Results

Actual EPS
-$3.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Liminatus Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Liminatus Pharma Q3 2025 Earnings FAQ

Liminatus Pharma (NASDAQ:LIMN) reported earnings of -$3.50 per share for Q3 2025. The report was announced on Friday, November 14, 2025.

Liminatus Pharma Earnings Headlines

Liminatus Pharma (NASDAQ:LIMN) Stock Jumps 7.9% - Still a Buy?
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Liminatus Pharma regains NASDAQ compliance
See More Liminatus Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email.

About Liminatus Pharma

Liminatus Pharma (NASDAQ:LIMN) is a biopharmaceutical company focused on developing immunotherapies for cancer. Its research centers on targets in the tumor microenvironment that can interfere with the body’s immune response to cancer.

The company’s lead program, LMP-001, is an antibody designed to target Galectin-9, an immune-regulating protein associated with tumor growth and immune suppression. Liminatus is also advancing a pipeline of cancer therapies based on its immuno-oncology research.

The company’s work is focused on drug development rather than marketed products, and its programs are intended for potential use across cancer types. Publicly available information about its geographic reach and leadership is limited.

View Liminatus Pharma Profile